Pfizer's Turnaround Has Truly Started (Earnings Update)

Pfizer reported a strong Q2 earnings beat with $0.78 EPS and $14.65 billion in revenue, a 10.3% Y/Y increase, driven by robust sales of key drugs like Paxlovid and Vyndaqel and aggressive cost-cutting initiatives targeting $7.2 billion in savings by 2027. The company raised its FY2025 EPS guidance, maintained its $0.43/share dividend, and strengthened its oncology pipeline with a significant licensing deal, signaling a turnaround despite a recent UK patent loss and ongoing drug pricing pressures. Its valuation metrics remain attractive, reinforcing a positive outlook.

Analysis

Pfizer's Q2 results demonstrate significant progress in its turnaround strategy, underscored by a substantial beat on both earnings and revenue. The company reported a non-GAAP EPS of $0.78 and revenue of $14.65 billion, a 10.3% year-over-year increase, driven by strong sales from key drugs like the Vyndaqel family (+21% Y/Y) and Paxlovid (+95%). This top-line strength is complemented by an aggressive cost-cutting program on track to deliver $7.2 billion in savings by 2027, which has helped improve gross margins and pushed the LTM net income margin to 16.84%. Management signaled confidence by raising its FY2025 EPS guidance despite potential tariff impacts and industry-wide drug pricing pressures. Strategically, Pfizer is bolstering its high-priority oncology portfolio through a licensing agreement with 3SBio, while maintaining a balanced capital allocation that prioritizes a 7.28% dividend yield and deleveraging over share repurchases in 2025. This positive operational momentum is tempered by a UK patent loss to Moderna, which creates a future liability for damages, and a narrower-than-hoped-for FDA approval for its Talzenna-Xtandi combination. Despite these headwinds, the company's valuation metrics, including a P/E of 7.32 and an improving FCF yield of 8.6%, remain significantly below industry medians.

Key Decisions for Investors

• Given the strong Q2 earnings, raised guidance, and successful cost-cutting, investors could view the stock as a compelling turnaround play with potential for re-rating.
• Income-focused investors should consider the high 7.28% dividend yield, the safety of which is reinforced by the recent strong financial performance and management's stated capital allocation priorities.
• It is prudent to monitor key risks, including the ultimate financial impact from the Moderna patent litigation, ongoing political pressure on drug pricing, and the lack of share buybacks which may limit short-term price support.
• The current valuation appears attractive relative to the sector, suggesting a potential entry point for those confident in the company's ability to sustain its operational momentum and execute on its pipeline.